[
    {
        "text": "i want to go back to a biomarker question we're going to talk about the apoe genotype at some point but of course one can actually measure apoe in the plasma you can actually just like you can measure apo lipoprotein b you which we use obviously extensively in cardiovascular risk stratification um to my knowledge there's not a commercial uh assay for measuring apoe though it can be done do you are you aware of any utility to that would that would looking at apoe levels i read a paper seven or eight years ago i think suggesting that the lower the level of apoe the higher the risk but i i could have i could entirely have that backwards and i could entirely be wrong but is that something you've you're aware of at all not really i mean it's really more about the genotyping than the quantification of it you know obviously and again you've talked about it on prior podcasts the the risk that e4 genotype carries compared to the others and the fact that e4 homozygotes have higher risk and also different responses to cardiovascular meds different different risks for other diseases besides dementia it is typically not something that we check for in a routine day-to-day clinical care for a couple of reasons one is it's not diagnostic right so you can have e4 e4 and not have alzheimer's or you can have e2 e3 which might be protective and still have alzheimer's so it really just makes people worry it",
        "start": "00:00:00",
        "duration": 212.95999999999998,
        "title": "The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia"
    },
    {
        "text": "does have a lot more utility in the research setting in terms of looking at how carriers versus non-carriers respond to certain treatments and helping us understand that carriers you know may respond differently to different lifestyle interventions may have an earlier onset compared to people who don't have it but ultimately end up with the same disease yeah so when people come to see you in clinic there's not a lot of utility added by looking at it i mean my view is apoe4 is great to help people identify risk early on but at the same time nobody gets off the hook and you used a great example the 2 3 shows up a lot and i tell my patients with the 2 3 you're not off the hook right you've got about a 10 risk reduction relative to the 3-3 but the 3-3 is clearly not at risk and on the flip side the 3-4 patients or even the four or four patients i say look it's certainly not a feta complete but i would take this a lot more seriously than maybe you otherwise would right in terms of preventative measures so let's go back to the patient that shows up in clinic oh actually there's one other thing i want to clarify i'm sorry let's go back to lewy body dementia most people have heard of this there have been some notable examples in the public uh sphere about you know folks that have died from this is it still the case that that's a diagnosis that can be made only post-mortem um i mean again yes but it is you know there's this sort of classic clinical picture that is so compelling that",
        "start": "00:01:47",
        "duration": 215.60100000000003,
        "title": "The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia"
    },
    {
        "text": "you know it it can be made fairly accurately in the clinic without diagnostic testing and so the clinical distinction between i hate to use this term the clinical distinction between classic alzheimer's dementia and classic lewy body so let's exclude the mixed variants of that how would you differentiate those patients so classic alzheimer's you know would begin with short-term memory loss and slowly but surely over time progress to having difficulty you know paying bills and then eventually needing supervision needing assistance with activities of daily living cooking bathing you know the classic sort of decline may or may not have behavior issues may or may not have some changes in walking lewy body disease on the other hand presents with a fairly classic triad of symptoms that occur within two years of one another one is an alzheimer's like cognitive impairment that can notably fluctuate so that some days people seem really good and some days they seem really really bad um there is a parkinsonism component where they will often be stiff have trouble rising from a chair shuffle they may decrease arm swing when they walk so that they walk and you know normally when we walk our arms move but their arms don't move they may have more less or i should say less expression on their face they don't necessarily have a tremor so true parkinson's disease proper often begins with a tremor a slow writhing kind of tremor at rest on one side um and often we don't see that in lewy body disease but these they have these other elements",
        "start": "00:03:33",
        "duration": 251.359,
        "title": "The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia"
    },
    {
        "text": "of parkinsonism and so we've got the the cognitive impairment the parkinsonism and very often prominent visual hallucinations um seeing things that aren't there fairly elaborate often delusions that go along with it you know there's this family living in my house there's people and bears living in the trees you know people will close their blinds because they don't want these people seeing them and all that kind of stuff so that classic triad of symptoms with some additional supportive features including restless leg syndrome even many years leading up to it as well as rem sleep behavior disturbances so people who often act out in their dreams or a spouse who says i have to sleep in the other room because he punches me you know that's sort of a classic louis body picture and and furthermore they fluctuate both the motor and the cognitive symptoms fluctuate so today we might be able to go to the mall and walk all around and tomorrow they might have trouble walking across the room and from the time of diagnosis amanda until those patients are either in hospice or incapacitated or dead is typically how long is that a quicker disease sometimes i mean it's usually about eight years um but for some it you know my experience i've had a lot of lewy body patients who have sort of this precipitous decline and then kind of hit a plateau for a while and then really drop off um you know this is not this is anecdotal this is not based on any data but it's just my experience with them",
        "start": "00:05:39",
        "duration": 235.99999999999991,
        "title": "The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia"
    },
    {
        "text": "and having seen enough of them to see that that's frequently kind of how it goes but it's usually about an eight to ten year process and they're it's less often as protracted as alzheimer's can be even though the average for alzheimer's is still also eight to ten years it can be significantly longer how hereditary is louis body dementia either with respect to lewy body itself or being predictive of the next generation's risk for alzheimer's disease or parkinson's for that matter um i honestly don't know i don't think it's terribly genetic you know we don't have well-established um you know as with early onset alzheimer's which does have some specific mutations that cause it i don't know that we know of specific mutations for lewy body disease but i may be just not informed i mean that makes in some ways lewy body a bit more of a mystery because as you said for alzheimer's disease on the very early onset side we have the psen1 to app mutations which are about as close to deterministic as you get and then you have the apo e4 gene which is not deterministic but is highly suggestive for the more typical variant and we also have known risk factors diabetes you know microvascular disease dyslipidemia i mean these things are absolutely known uh risk factors we seem to have none of that on the side of lewy body correct as far as i know yeah what's the relative incidence of alzheimer's versus lewy body dementia is it like eight ten to one or how how much more prominent is alzheimer's um well it",
        "start": "00:07:37",
        "duration": 221.60000000000002,
        "title": "The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia"
    },
    {
        "text": "depends i guess if you're looking at uh you know the autopsy confirmed versus sort of what we see in the clinic um you know i think that i honestly don't have the numbers specifically for you but i i do know that you know it's diagnosed less but found more on autopsy that people do have lewy bodies that we may not have expected i got it and just in your experience in your clinic what's the approximate distribution of those the the it's about i would say um you know 50 to 60 plus percent alzheimer's about 20 percent true vascular about 20 lewy body and then the rest is ftd and some of these parkinson's plus syndromes um progressive supernuclear palsy and some of these other less common things that we only see once in a while so back to kind of the way your practice works presumably people are coming to you at the referral of a neurologist correct not necessarily no um we get people referred from their primary doctors we get people that are self-referred um we get people that are referred by neurology it varies widely this podcast is for general informational purposes only and does not constitute the practice of medicine nursing or other professional health care services including the giving of medical advice no doctor-patient relationship is formed the use of this information and the materials linked to this podcast is at the user's own risk the content on this podcast is not intended to be a substitute for",
        "start": "00:09:28",
        "duration": 219.75999999999996,
        "title": "The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia"
    },
    {
        "text": "professional medical advice diagnosis or treatment users should not disregard or delay in obtaining medical advice from any medical condition they have and they should seek the assistance of their health care professionals for any such conditions finally i take conflicts of interest very seriously for all of my disclosures and the companies i invest in or advise please visit petertiammd.com forward slash about where i keep an up-to-date and active list of such companies",
        "start": "00:11:20",
        "duration": 73.039,
        "title": "The significance of ApoE genotype, and differentiating Alzheimer’s disease from Lewy body dementia"
    }
]